BridgeBio Pharma Inc (BBIO)’s stock is trading at $25.68 at the moment marking a fall of -5.54% from the last session close. As of this writing, shares are priced at -42.05% less than their 52-week high of $44.32, and 18.80% over their 52-week low of $21.62. Based on the past 30-day period, the stock price is -15.42% below the high and +18.81% above the low.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, BBIO’s SMA-200 is $27.17.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Further, it is important to consider BBIO stock ratios, particularly its price-to-sales ratio over the past twelve months, which stands at 22.29.
How does BridgeBio Pharma Inc (BBIO) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 17 brokerage firms that recommend the stock as a Strong Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 4.71 in simple terms.
BridgeBio Pharma Inc (BBIO): Earnings History
Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 8 different analysts, who are expecting earnings to fall in between the range of -0.90 and -1.27 with an average Earnings Estimate of -1.08 which is in contrast with the last year earnings estimate of -0.96 and also replicates -12.50% growth rate year over year.
BridgeBio Pharma Inc (NASDAQ: BBIO) Ownership Details
I will give a breakdown of the key shareholders in BridgeBio Pharma Inc (BBIO). Recent figures show that the company’s insiders hold 5.40% of shares. A total of 349 institutional investors hold shares in the company, making 94.45% of its stock and 99.84% of its float.
Sep 30, 2024, it was reported that the Company’s largest institutional holder is Kohlberg Kravis Roberts & Co. L.P. holding total of 25.26 shares that make 13.37% of the company’s total number of shares and are currently priced at 658.55 million.
The securities firm Viking Global Investors, L.P. holds 25.12 shares of BBIO, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 13.29%, and the holding percentage of shares is valued at 654.9 million.
An overview of BridgeBio Pharma Inc’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests BridgeBio Pharma Inc (BBIO) traded 2,466,275 shares per day, with a moving average of $24.65 and price change of +1.31. With the moving average of $24.96 and a price change of -0.92, about 2,032,230 shares changed hands on average over the past 50 days. Finally, BBIO’s 100-day average volume is 1,946,669 shares, alongside a moving average of $25.72 and a price change of -0.33.
